Ovid Therapeutics - OVID Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" OVID shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OVID, but not buy additional shares or sell existing shares.
View OVID analyst ratings or view top-rated stocks.

1 brokerages have issued 12-month price targets for Ovid Therapeutics' stock. Their OVID share price forecasts range from $2.50 to $2.50. On average, they expect the company's stock price to reach $2.50 in the next twelve months. This suggests that the stock has a possible downside of 1.6%.
View analysts price targets for OVID or view top-rated stocks among Wall Street analysts.

Ovid Therapeutics' stock was trading at $1.86 at the beginning of the year. Since then, OVID stock has increased by 36.6% and is now trading at $2.54.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our OVID earnings forecast.

Ovid Therapeutics Inc. (NASDAQ:OVID) announced its quarterly earnings results on Monday, March, 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.01. The company had revenue of $0.05 million for the quarter.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), SCYNEXIS (SCYX), Enphase Energy (ENPH), Gilead Sciences (GILD) and Novavax (NVAX).

(OVID) raised $80 million in an IPO on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Ovid Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Madison Avenue Partners LP (3.86%), Geode Capital Management LLC (0.71%), Wells Fargo & Company MN (0.61%), Millennium Management LLC (0.20%), Tejara Capital Ltd (0.15%) and Jane Street Group LLC (0.08%). Insiders that own company stock include Amit Rakhit, Jason Tardio and Jeremy M Levin.
View institutional ownership trends.

Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OVID stock can currently be purchased for approximately $2.54.

Ovid Therapeutics (NASDAQ:OVID) has a market capitalization of $179.04 million and generates $1.50 million in revenue each year. The company earns $-54,170,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The official website for the company is www.ovidrx.com. The company can be reached via phone at (646) 661-7661 or via email at investors@ovidrx.com.